MORRISTOWN, N.J., March 31, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it is initiating launch activities of Nulecit™ (sodium ferric gluconate complex in sucrose injection), following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application (ANDA). Nulecit is the first bioequivalent and therapeutically equivalent alternative to Sanofi-Aventis' Ferrlecit®. In July 2009 Watson signed a license agreement with GeneraMedix for the exclusive U.S. marketing rights to the product, which will be marketed by Watson's Global Brands business.
Nulecit is approved for the treatment of iron deficiency anemia in adults and children age six years or older undergoing chronic hemodialysis who are receiving supplemental epoetin therapy. It will offer the convenience and cost savings of administration from a single-dose glass vial, minimizing the need for filter needles or a required test dose.
The branded alternative to Nulecit is currently available only in 5 mL glass ampules that require the tops to be broken off manually before administration, and many protocols require that the product withdrawn with a syringe using a filter needle.
"Watson's Brand sales team is uniquely positioned to effectively maximize the opportunities of this value brand offering, given our experience in marketing injectable iron products," said Fred Wilkinson, Executive Vice President, Global Brands, at Watson. "Nulecit offers the nephrology community a value brand that is bioequivalent to the innovator product, with the added convenience of packaging in glass vials."
Efficacy with Added ConvenienceIn the bioequivalence study, which involved 240 healthy volunteers, Nulecit and Ferrlecit showed comparable concentrations of total serum iron and transferrin-bound iron over 36 hours. Each 5 mL glass vial of Nulecit contains a 62.5-mg single dose (12.5 mg of elemental iron per mL). Additionally, data supports stability of Nulecit in both syringes and saline bags.
"A vial dosage form of sodium ferric gluconate is an important step forward in the treatment of patients with IV iron vs. the old ampule," said Rajiv Agarwal, a board certified nephrologist and professor of medicine at Indiana University School of Medicine. "Having the 62.5 mg vial is convenient for ongoing or continuous therapy, which is our standard with dialysis patients today and may help to control costs by optimizing delivery and minimizing waste."
The 62.5-mg vial of Nulecit is convenient when IV iron is administered in regular low doses, as in a continuous dosing regimen. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™) guidelines for the administration of parenteral iron suggest that an average of 22 to 65 mg of iron per week are required to achieve neutral iron balance and maintenance of stable serum ferritin values in hemodialysis patients.
Important Safety InformationSodium ferric gluconate complex in sucrose is contraindicated in non iron-deficient anemias, in patients hypersensitive to sodium ferric gluconate complex in sucrose or its inactive components, or with evidence of iron overload. Hypersensitivity reactions have been reported with injectable iron products. Hypotension has been reported with rapid administration of IV iron. In a single-dose, placebo-controlled safety study (n=1097), the most frequent adverse events occurring after sodium ferric gluconate complex in sucrose administration were hypotension, nausea, and vomiting and/or diarrhea In multiple-dose studies (n=126), the most frequent adverse events, whether or not related to sodium ferric gluconate complex in sucrose administration were nausea, vomiting and/or diarrhea, injection site pain, hypotension, cramps, hypertension, dizziness, dyspnea, and chest pain.
About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com/.
Watson Forward-Looking StatementStatements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson, its subsidiaries, and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid affecting, among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.
* Ferrlecit® is a registered trademark of A. Nattermann & Cie. GmbH
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty EisenhaurWatson Pharmaceuticals, Inc. (973) 355-8141Media:Charlie MayrWatson Pharmaceuticals, Inc. (973) 355-8483
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved